About this medicine

Dexmethylphenidate contains one active mirror-image form of methylphenidate. It can improve attention and reduce impulsive or hyperactive symptoms in ADHD, but the chemical relationship does not justify an unsupervised conversion from another stimulant.

The NHS SPS catalogue lists a US-imported Focalin XR capsule. NHS dm+d and current pharmacy guidance identify this Imported (country) naming convention with unlicensed imports. That evidence supports the named product's import context; it does not establish a complete list of every UK authorisation, current stock or NHS funding.

What is this medicine used for?

Focalin and Focalin XR have US ADHD indications. That foreign authorisation is not MHRA authorisation, and the narcolepsy indication of some other methylphenidate products cannot be transferred to dexmethylphenidate.

In UK practice, an unlicensed medicine may be considered for a patient's specific clinical need when a suitable licensed treatment cannot meet it. This is not a routine recommendation to import Focalin. The prescriber must assess the evidence, explain the decision and arrange responsibility for care.

Which warning signs need help?

Misuse can cause overdose, addiction and death. Keep the medicine secure, do not share it and seek advice on safe disposal. The US boxed-warning format is a foreign regulatory designation, not an MHRA boxed warning.

Chest pain, fainting, breathlessness, seizures, severe allergy, severe agitation or suspected overdose needs urgent or emergency assessment. A prolonged painful erection, sudden eye pain or visual change also requires prompt medical attention.

New hallucinations or mania, worsening tics and cold, painful or discoloured fingers or toes need review. Seek immediate help if the person cannot remain safe. These safety concerns are relevant to the ingredient even when the product is supplied through an import route.

How do I take it safely?

The reviewed NHS catalogue entry describes an imported modified-release capsule. Focalin immediate-release tablets also have a separate US label; their existence does not establish UK tablet supply.

The US XR instructions permit swallowing the capsule whole or sprinkling all its contents on apple sauce, swallowed promptly without chewing or storing the mixture. Do not divide the contents. For an actual imported supply, the pharmacist must confirm the exact preparation and its instructions; no numerical titration or maximum dose is reproduced here.

What side effects should I know about?

Reduced appetite, abdominal discomfort, nausea, headache, anxiety and difficulty sleeping can occur. Weight loss or slower weight gain matters particularly in children.

Persistent effects should be discussed with the prescriber rather than managed by taking extra doses, changing release formulations or stopping abruptly. A listed possible effect is not a prediction that everyone will experience it.

Who needs extra care with this medicine?

The foreign labels contraindicate hypersensitivity to the product or methylphenidate and treatment with an MAOI, including within the preceding fourteen days. Serious cardiac disease can make stimulant treatment unsafe.

Assessment should consider blood pressure, heart and family sudden-death history, bipolar or psychotic illness, tics, seizures, glaucoma, growth and vulnerability to misuse. This is not an exhaustive eligibility checklist; the actual product information and individual history are needed.

Can it affect my other medicines?

MAO inhibitors can cause a dangerous rise in blood pressure when combined with this stimulant. Dexmethylphenidate may reduce the effect of blood-pressure medicines, and some anaesthetics create additional cardiovascular risk.

The current XR label also notes movement-disorder risk when methylphenidate and risperidone doses change. Tell the prescriber and anaesthetist about all medicines, supplements and planned procedures. An unlisted combination should not be assumed safe.

What check-ups will I need?

Monitoring should track symptoms and functioning, sleep, appetite, weight, pulse and blood pressure; children also need height and growth assessment. Mental-state changes, tics, adverse effects and misuse concerns require review.

For an unlicensed imported medicine, the prescriber, pharmacy and patient need a clear plan for follow-up and continuity. An overseas prescription or catalogue entry does not automatically transfer prescribing responsibility to a UK GP. This article does not prescribe a fixed UK monitoring timetable.

What about pregnancy, breastfeeding and age?

Pregnancy and breastfeeding need an individual benefit–risk discussion. Limited milk information comes mainly from methylphenidate, not a guarantee that every dexmethylphenidate exposure is harmless. Infant feeding, sleep, agitation and weight gain may need review.

The current US XR label does not recommend use below six years because younger children can have greater exposure and adverse effects. This is a foreign age boundary, not a UK licensed indication. Children require growth follow-up; experience in older adults is limited.

What if I miss a dose or want to stop?

After prolonged use, abrupt stopping or a large reduction can cause low mood, fatigue, disturbed sleep, increased appetite and slowing or agitation. Plan changes with the prescriber and obtain urgent help for severe depression or inability to stay safe.

Follow the supplied product's missed-dose instructions and never double a dose. Late catch-up dosing may disturb sleep. Review continuing need with the clinician rather than taking unsupervised treatment breaks.

How does it work?

Dexmethylphenidate changes the handling of dopamine and noradrenaline, chemical messengers used by nerve cells. It reduces their reuptake, the return into cells after release, leaving more available between cells. It is the more active of the two mirror-image molecular forms found in methylphenidate, with the same atoms arranged differently in space.

The full explanation of how these actions improve attention-deficit/hyperactivity disorder (ADHD) symptoms is not known. Their effect on communication between cells does not show that someone has a simple messenger shortage. A medicine response also cannot replace an assessment of the person’s difficulties and their impact on everyday life.

How does it affect my body?

Pharmacodynamics describes what a medicine does to the body. Benefit is judged through attention, impulsivity and everyday functioning across relevant settings, rather than alertness alone.

Appetite suppression or sleep disruption may appear early. Blood pressure and pulse can rise. Irritability, new psychotic or manic symptoms, tics and changes in growth require reassessment alongside any benefit; increasing the dose is not automatically the answer.

How does my body process it?

Pharmacokinetics describes absorption, breakdown and removal. Dexmethylphenidate is mainly de-esterified to largely inactive d-ritalinic acid. Extended release prolongs absorption rather than turning it into a different active molecule.

Focalin XR produces two concentration peaks through its release system. Chewing or crushing its beads can interfere with delivery. These foreign formulation observations are not a UK dose schedule or a conversion rule for another methylphenidate product.

How do treatment options differ?

Racemic methylphenidate and dexmethylphenidate are related but are not milligram-for-milligram substitutes. Differences in active stereoisomer, release system and individual response matter.

An overseas conversion instruction is not a universal switching rule. A switch needs the exact products and clinical plan; it must not be inferred from a brand alias or from the fact that two medicines belong to the methylphenidate family.

A closer look at the science

The d-threo stereochemistry distinguishes dexmethylphenidate from racemic methylphenidate, which contains both mirror-image forms. Dexmethylphenidate is the more pharmacologically active component. Its ester group is broken down during metabolism, while hydrochloride describes the salt used in the foreign preparations.

Molecular identity and release design are separate: an immediate-release tablet and an extended-release capsule can contain the same active ingredient but deliver it differently.

How was this medicine developed?

The US Focalin label records an initial US approval in 2001. Subsequent XR development changed delivery by combining earlier and later release, not by creating a new neurotransmitter target.

Current foreign labelling includes strengthened misuse precautions and the newer extended-release warning for young children. These developments explain why an old prescription or brand familiarity cannot substitute for checking the current product. UK import catalogue terminology describes a different regulatory question from the US approval history.

Sources and References

  1. Focalin XR 10mg capsules (Imported (United States)): actual medicinal product

    Scope: United Kingdom medicine catalogue; named US-imported product.

  2. Focalin XR: current US prescribing information

    Scope: United States; foreign formulation, science and safety evidence only.

  3. Focalin immediate-release tablets: US prescribing information

    Scope: United States; foreign product distinction and scientific comparison only.

  4. Dexmethylphenidate: patient medicine information

    Scope: United States; general safety education only.

  5. dm+d Implementation Guide (Primary Care), version 2.0

    Scope: England prescribing terminology; UK medicine-product catalogue context.

  6. Unlicensed specials and imports

    Scope: England electronic prescription and dispensing terminology.

  7. Understanding unlicensed medicines

    Scope: United Kingdom medicines governance.

  8. Prescribing unlicensed medicines

    Scope: United Kingdom professional prescribing standards.

  9. Schizophrenia
  10. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top